Head & neck

The ETHICON™ Total Energy System is now referred to as DUALTO™ Energy System, with no changes to its intended use, design, performance, 
or regulatory status under FDA 510(k) K243067.

SURGICEL™ Essential Product Information

INDICATIONS

SURGICEL™ Absorbable Hemostat (oxidized regenerated cellulose) is used adjunctively in surgical procedures to assist in the control of capillary, venous, and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective. SURGICEL™ ORIGINAL, SURGICEL™ FIBRILLAR™, SURGICEL NU-KNIT™, and SURGICEL SNoW™  Hemostats can be cut to size for use in endoscopic procedures.

CONTRAINDICATIONS

• Although packing or wadding sometimes is medically necessary, SURGICEL™ Absorbable Hemostat should not be used in this manner, unless it is to be removed after hemostasis is achieved (See WARNINGS and PRECAUTIONS).
• SURGICEL™ Absorbable Hemostat should not be used for implantation in bone defects, such as fractures, since there is a possibility of interference with callus formation and a theoretical chance of cyst formation.
• When SURGICEL™ Absorbable Hemostat is used to help achieve hemostasis in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, or the optic nerve and chiasm, it must always be removed after hemostasis is achieved since it will swell and could exert unwanted pressure.
• SURGICEL™ Absorbable Hemostat should not be used to control hemorrhage from large arteries.
• SURGICEL™ Absorbable Hemostat should not be used on non-hemorrhagic serous oozing surfaces, since body fluids other than whole blood, such as serum, do not react with SURGICEL™ Absorbable Hemostat to produce satisfactory hemostatic effect.
• SURGICEL™ Absorbable Hemostat is an absorbable hemostat, and should not be used as an adhesion prevention product.

Warnings and Precautions

• SURGICEL™ Absorbable Hemostat is supplied sterile and as the material is not compatible with autoclaving or ethylene oxide sterilization, SURGICEL™ Absorbable Hemostat should not be resterilized.

• SURGICEL™ Absorbable Hemostat is not intended as a substitute for careful surgery and the proper use of sutures and ligatures.
• Closing SURGICEL™ Absorbable Hemostat in a contaminated wound may lead to complications and should be avoided.
• The hemostatic effect of SURGICEL™ Absorbable Hemostat is greater when it is applied dry; therefore it should not be moistened with water or saline.
• SURGICEL™ Absorbable Hemostat should not be impregnated with anti-infective agents or with other materials such as buffering or hemostatic substances. Its hemostatic effect is not enhanced by the addition of thrombin, the activity of which is destroyed by the low pH of the product.
• Although SURGICEL™ Absorbable Hemostat may be left in situ when necessary, it is advisable to remove it once hemostasis is achieved. It must always be removed from the site of application when used in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm, and in proximity to tubular structures that could become constricted by swelling, regardless of the type of surgical procedure because SURGICEL™ Hemostat, by swelling, may exert pressure resulting in paralysis and/or nerve damage. Dislodgement of SURGICEL™ Absorbable Hemostat could possibly occur by means such as repacking, further intraoperative manipulation, lavage, exaggerated respiration, etc. There have been reports that in procedures such as lobectomy, laminectomy and repair of a frontal skull fracture and lacerated lobe that SURGICEL™ Absorbable Hemostat, when left in the patient after closure, migrated from the site of application into foramina in bone around the spinal cord resulting in paralysis and, in another case, the left orbit of the eye, causing blindness. While these reports cannot be confirmed, special care must be taken by physicians, regardless of the type of surgical procedure, to consider the advisability of removing SURGICEL™ Absorbable Hemostat after hemostasis is achieved.
• Although SURGICEL™ Absorbable Hemostat is bactericidal against a wide range of pathogenic microorganisms, it is not intended as a substitute for systemically administered therapeutic or prophylactic antimicrobial agents to control or prevent post-operative infections.

PRECAUTIONS

• Use only as much SURGICEL™ Absorbable Hemostat as is necessary for hemostasis, holding it firmly in place until bleeding stops. Remove any excess before surgical closure in order to facilitate absorption and minimize the possibility of foreign body reaction, such as encapsulation of the product, which may mimic artifacts on radiographic images, resulting in diagnostic errors and possible reoperation.
• In urological procedures, minimal amounts of SURGICEL™ Absorbable Hemostat should be used and care must be exercised to prevent plugging of the urethra, ureter, or a catheter by dislodged portions of the product.
• Since absorption of SURGICEL™ Absorbable Hemostat could be prevented in chemically cauterized areas, its use should not be preceded by application of silver nitrate or any other escharotic chemicals.
• If SURGICEL™ Absorbable Hemostat is used temporarily to line the cavity of large open wounds, it should be placed so as not to overlap the skin edges. It should also be removed from open wounds by forceps or by irrigation with sterile water or saline solution after bleeding has stopped.
• Precautions should be taken in otorhinolaryngologic surgery to assure that none of the material is aspirated by the patient.  (Examples: controlling hemorrhage after tonsillectomy and controlling epistaxis.)
• Care should be taken not to apply SURGICEL™ Absorbable Hemostat too tightly when it is used as a wrap during vascular surgery (see ADVERSE REACTIONS).

ADVERSE REACTIONS

• “Encapsulation” of fluid and foreign body reactions have been reported.
• There have been reports of stenotic effect when SURGICEL™ Absorbable Hemostat has been applied as a wrap during vascular surgery. Although it has been established that the stenosis was directly related to the use of SURGICEL™ Absorbable Hemostat, it is important to be cautious and avoid applying the material tightly as a wrapping.
• Paralysis and nerve damage have been reported when SURGICEL™ Absorbable Hemostat was used around, in, or in proximity to foramina in bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm. While most of these reports have been in connection with laminectomy, reports of paralysis and nerve damage have also been received in connection with other procedures such as thyroidectomy. Blindness has been reported in connection with surgical repair of a lacerated left frontal lobe when SURGICEL™ Absorbable Hemostat was placed in the anterior cranial fossa (See WARNINGS and PRECAUTIONS). 
• Possible prolongation of drainage in cholecystectomies and difficulty passing urine per urethra after prostatectomy have been reported. There has been one report of a blocked ureter after kidney resection, in which postoperative catheterization was required.
• Occasional reports of “burning” and “stinging” sensations and sneezing when SURGICEL™ Absorbable Hemostat has been used as packing in epistaxis, are believed to be due to the low pH of the product.
• Burning has been reported when SURGICEL™ products were applied after nasal polyp removal and hemorrhoidectomy. Headache, burning, stinging, and sneezing in epistaxis and other rhinological procedures, and stinging when SURGICEL™ Absorbable Hemostat was applied on surface wounds (varicose ulcerations, dermabrasions, and donor sites) have also been reported.

For more information, call 1-800-795-0012.  For complete product information including indications, contraindications, warnings, precautions, and adverse reactions, and directions for use, please consult the product package inserts.

VISTASEAL™ Fibrin Sealant (Human) IMPORTANT SAFETY INFORMATION

INDICATION

VISTASEAL™, a fibrin sealant, is indicated as an adjunct to hemostasis for mild to moderate bleeding in patients undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. VISTASEAL™ is effective in heparinized patients.

CONTRAINDICATIONS

Do not inject directly into the circulatory system.

Do not use for the treatment of severe or brisk arterial bleeding.

Do not use in patients with history of anaphylaxis or severe systemic reactions to human blood products.

Do not use VISTASEAL™ for spraying unless the minimum recommended distance from the applicator tip to the bleeding site can be achieved.

WARNINGS AND PRECAUTIONS 

Thromboembolic events may occur if VISTASEAL™ is administered intravascularly.

Hypersensitivity reactions can occur.

May carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

ADVERSE REACTIONS

The most common adverse reactions (reported in >1% of patients) were procedural pain, and nausea.



For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

A Sealing of ex vivo 5-7mm diameter porcine vessels showed median burst pressure of >1800 mmHg.

B. In a pre-clinical summative usability study, with surgeons (n=33) that went through an end-to-end procedure and afterward responded to a series of statements regarding the DUALTO™ Energy System.

1. Ethicon, Project Gemini: Claim Rationale. 07/19/2022. Windchill Document #501001842.
2. Ethicon, Harmonic 700 Claims Rationale Design History File Memo for Project Gemini. 05/16/2022. Windchill Document #500951334.
3. Ethicon, Gemini Claims Testing - Burst Pressure/Sealing. 08/02/2022. Windchill Document #500648351.
4. HARMONIC FOCUS™+ Shears Instructions for Use. Johnson and Johnson MedTech.
5. Ethicon, Several HARMONIC FOCUS Long Curved Shears, 17cm Length (FCS17) approved claims shall also apply to HARMONIC FOCUS Long Shears+ Adaptive Tissue Technology, 17cm (HAR17F) based on similarity of design. 07/29/2015. Research & Development Memo.
6. Johnson & Johnson and its affiliates, DUALTO Energy System Marketing Claims Report. 03/20/2025. Windchill Document #501949635.
7. Ethicon Communications Module, Ethicon User Screen, and Ethicon Energy Cart Operator's Manual.
8. VISTASEAL™ Fibrin Sealant (Human). Full Prescribing Information. Instituto Grifols, S.A.
9. Bjelovic M, Ayguasonosa J, Kim RD, et al. A prospective, randomized, phase III study to evaluate the efficacy and safety of fibrin sealant Grifols as an adjunct to hemostasis as compared to cellulose sheets in hepatic surgery resections. J Gastrointest Surg. 2018;22:1939-1949.
10. Nenezic D, Ayguasonosa J, Menyhei G, et al. A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols as an adjunct to hemostasis compared with manual compression in vascular surgery. J Vasc Surg. 2019: doi.org_10.1016_j.jvs.2018.12.051.
11. Lakshman S, Aqua K, Stefanovic A, et al. A prospective, single blind, randomized, phase III study to evaluate the safety and efficacy of fibrin sealant Grifols as an adjunct to hemostasis during soft tissue open surgery. J Invest Surg. 2018;DOI:10.1080_08941939.2018.1489917.